Growth Metrics

Pfizer (PFE) Non-Current Debt (2016 - 2025)

Pfizer (PFE) has disclosed Non-Current Debt for 17 consecutive years, with $57.4 billion as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 1.02% to $57.4 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $57.4 billion, a 1.02% decrease, with the full-year FY2024 number at $57.0 billion, down 7.37% from a year prior.
  • Non-Current Debt was $57.4 billion for Q3 2025 at Pfizer, roughly flat from $57.5 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $61.5 billion in Q4 2023 to a low of $31.7 billion in Q2 2023.
  • A 5-year average of $47.4 billion and a median of $57.0 billion in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: plummeted 30.03% in 2021, then soared 93.37% in 2024.
  • Pfizer's Non-Current Debt stood at $36.2 billion in 2021, then dropped by 9.15% to $32.9 billion in 2022, then skyrocketed by 87.14% to $61.5 billion in 2023, then decreased by 7.37% to $57.0 billion in 2024, then grew by 0.72% to $57.4 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Non-Current Debt are $57.4 billion (Q3 2025), $57.5 billion (Q2 2025), and $57.6 billion (Q1 2025).